Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA5 | P11021 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | TYR | P14679 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415372 | 0.86 | HSPA5 (1.00) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL29351672 | 0.86 | HSPA5 (1.00) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL29558774 | 0.86 | HSPA5 (0.78) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL34162 | 0.86 | HSPA5 (1.00) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL2230912 | 0.86 | HSPA5 (0.78) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| Ethylene Glycol SCHEMBL11769531 | 0.85 | HSPA5 (0.89) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL11330811 | 0.85 | HSPA5 (0.70) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL11247674 | 0.84 | CYP2C9 (1.00) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL29410654 | 0.84 | HSPA5 (0.96) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A | |
| SCHEMBL30123824 | 0.84 | HSPA5 (0.75) | HSPA5CYP2C9CYP2C19SMN1; SMN2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116693578-B | Iron-based complex and preparation method thereof, and method for preparing polycarbonate and catalyzing polymerization of epoxy cyclohexane and phthalic anhydride by catalysis | 中国石油大学(北京) | 2025-04-22 | — | — | CN | disclosed |
| CN-116693578-A | Iron-based complex and preparation method thereof, and method for preparing polycarbonate and catalyzing polymerization of epoxy cyclohexane and phthalic anhydride by catalysis | 中国石油大学(北京) | 2023-09-05 | — | — | CN | disclosed |
| US-8193249-B2 | Triptolide analogs for the treatment of autoimmune and inflammatory disorders | EMORY UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193249-B2 | Triptolide analogs for the treatment of autoimmune and inflammatory disorders | EMORY UNIVERSITY (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100324133-A1 | Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders | LIOTTA DENNIS C | 2010-12-23 | — | — | US | disclosed |
| US-20100324133-A1 | Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders | LIOTTA DENNIS C | 2010-12-23 | — | — | US | disclosed |
| US-20090234000-A1 | Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders | WANG SUSHENG | 2009-09-17 | — | — | US | disclosed |
| US-20090234000-A1 | Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders | WANG SUSHENG | 2009-09-17 | — | — | US | disclosed |
| WO-2009089285-A2 | BRANCHED DIEPOXIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | EMORY UNIVERSITY (US) | 2009-07-16 | — | — | WO | disclosed |
| US-7557139-B2 | Triptolide analogs for the treatment of autoimmune and inflammatory disorders | EMORY UNIVERSITY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557139-B2 | Triptolide analogs for the treatment of autoimmune and inflammatory disorders | EMORY UNIVERSITY (US) | 2009-07-07 | — | — | US | disclosed |
| EP-0104643-A2 | 5-Membered cyclic phosphonates and compositions thereof | The B.F. GOODRICH Company (US) | 1984-04-04 | — | — | EP | disclosed |
| US-4439564-A | 5-Membered cyclic phosphonates and compositions thereof | THE B. F. GOODRICH CO. (US) | 1984-03-27 | — | — | US | disclosed |
| US-4035435-A | FORMALDEHYDE, RESORCINOL | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN, RAISON SOCIALE MICHELIN & CIE (FR) | 1977-07-12 | — | — | US | disclosed |
| US-4025454-A | PHENOLIC RESIN BLEND | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN, RAISON SOCIALE MICHELIN & CIE (FR) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324133-A1 | Branched Diepoxide Compounds for the Treatment of Inflammatory Disorders | HPGDS, LTB4R2, TNF | HSPA5 1969/4885CYP2C9 2309/4885CYP2C19 1857/4885 |
| US-20090234000-A1 | Triptolide Analogs for the Treatment of Autoimmune and Inflammatory Disorders | SSB, ENPP2, NOD1 | HSPA5 3140/4885CYP2C9 2144/4885CYP2C19 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.